• Arch Intern Med · Nov 1994

    The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.

    • Arch Intern Med. 1994 Nov 14;154(21):2484-91.

    BackgroundAntiendotoxin monoclonal antibodies are under investigation as adjunctive therapy for severe sepsis. One of these antibodies (the human IgM monoclonal antibody HA-1A) was marketed in Europe during 1992 for treatment of patients with severe sepsis, especially those with shock, and probable gram-negative bacilli (GNB) bacteremia, after a placebo-controlled trial showed improved outcome in such patients. This cohort study was designed to assess characteristics and determinants of outcome of patients through a nationwide registry of all adult patients hospitalized in intensive care units of French hospitals and treated with HA-1A.MethodsMain outcome measures included (1) survival at 14 days, 28 days, and hospital discharge, with comparison of observed with expected hospital mortality according to the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and (2) analysis of risk factors for death using a Cox proportional hazards model.ResultsOf 600 patients who received HA-1A in a 1-year period, 75% had documented GNB infection and 39% had GNB bacteremia; 94% had hypotension and 54% had refractory shock. Crude overall mortality rates were 49% and 61.3% (P < 10(-4)) at day 14 after therapy and hospital discharge, respectively. Hospital mortality tended to be higher than expected from the APACHE II score (61.3% vs 56%, P = .06), especially in patients without GNB infection (68.1% vs 58.3%). Independent risk factors for death were the APACHE II score (P < 10(-4)), the number of organ system failures (P = 10(-4)), the prognosis of underlying disease (P = .001), and non-GNB infection (relative risk, 1.32 [95% confidence interval, 1.05 to 1.66]; P = .02).ConclusionsThis cohort study did not confirm decreased mortality in patients with GNB bacteremia, as reported in the first placebo-controlled HA-1A trial, and it further suggests excess mortality in the subgroup of patients with non-GNB infection. In clinical trials of patients with severe sepsis, controlling for both the severity of acute illness score and the number of organ system failures, as well as for the severity of underlying disease and the source of infection, should be considered, especially when subgroups are analyzed.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.